Status:
COMPLETED
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
Lead Sponsor:
Pfizer
Conditions:
Impotence
Eligibility:
MALE
18-65 years
Phase:
PHASE2
Brief Summary
To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 ...
Eligibility Criteria
Inclusion
- Erectile dysfunction as defined by DSM-IV. Patients should have been PDE5 inhibitor respondents
Exclusion
- Alpha blockers and Nitrates of any preparation
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00141349
Start Date
February 1 2005
End Date
August 1 2005
Last Update
July 25 2006
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35205
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209-5603
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35215
4
Pfizer Investigational Site
Mesa, Arizona, United States, 85201